Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Dermatologic 1

Conditions

Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Retinoblastoma 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Pancreatic Neoplasms 1Osteoporosis 1Obesity 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

Cisplatin 88Fluorouracil 71Paclitaxel 69Radiotherapy 63Oxaliplatin 55Irinotecan 37Docetaxel 36Carboplatin 36Leucovorin 34Capecitabine 28Radiation 25Surgical Procedures, Operative 22Drug Therapy 19pembrolizumab 18Cetuximab 15Bevacizumab 15Nivolumab 14tislelizumab 12camrelizumab 11Neoadjuvant Therapy 11Esophagectomy 11Chemoradiotherapy 11S 1 (combination) 10Albumin-Bound Paclitaxel 10nimotuzumab 9Trastuzumab 9durvalumab 8Radiotherapy, Intensity-Modulated 8Gefitinib 7Epirubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Neoplasms × Observation × Clear all
NCT06933966 2025-04-18

ATTENUATION

Centre Leon Berard

Phase 2 Not yet recruiting
120 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT06272214 2024-07-16

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Zhejiang Cancer Hospital

Phase 2 Recruiting
146 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡